Exhibit 10.2


 


April 24, 2020


 


Hancock Jaffe Laboratories, Inc.


70 Doppler


Irvine, CA 92618


Attn: Robert A. Berman, Chief Executive Officer


 


Dear Mr. Berman:


 


This letter (the “Agreement”)
constitutes the agreement between Spartan Capital Securities, LLC (“Spartan” or the “Placement Agent”)
and Hancock Jaffe Laboratories, Inc. (the “Company”), that Spartan shall serve as the exclusive placement agent
for the Company, on a “reasonable best efforts” basis, in connection with in any offering (each, a “Placement”)
of securities of the Company during the Term (as hereinafter defined) of this Agreement. The terms of each Placement and the securities
issued in connection therewith shall be mutually agreed upon by the Company and Spartan and nothing herein implies that Spartan
would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue
any securities. The initial proposed Placement of securities is comprised of (i) registered shares (the “Shares”)
of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and (ii) unregistered
warrants to purchase shares of Common Stock (the “Warrants”, together with the Shares the “Securities”).
The terms of the Placement and the Securities, including the Company’s obligation to file a resale registration statement
on Form S-1 with regard to the shares of Common Stock underlying the Warrants for the benefit of the Purchasers (as defined in
this sentence), shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively,
the “Purchasers”) and nothing herein constitutes that Spartan would have the power or authority to bind the
Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and
the documents executed and delivered by the Company and the Purchasers in connection with the Placement shall be collectively referred
to herein as the “Transaction Documents.” The date of the closing of the Placement shall be referred to herein
as the “Closing Date.” The Company expressly acknowledges and agrees that Spartan’s obligations hereunder
are on a “reasonable best efforts” basis only and that the execution of this Agreement does not constitute a commitment
by Spartan to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or
the success of Spartan with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other
brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement.


 


SECTION 1. COMPENSATION.


 


A. Cash and Warrant Coverage.
At the Closing of each Placement (each, a “Closing”) the Company will pay Spartan: (i) a cash fee equal to 8% of the
gross proceeds received by the Company from the sale of the Securities to investors introduced to the Company by Spartan, which
shall be deemed to include all investors for which Spartan provides executed Transaction Documents to the Company; and (ii) a number
of warrants equal to the quotient obtained by dividing 8.0% of the gross proceeds paid for the Securities issued by the Company
divided by the purchase price paid by the Purchasers for such Securities (the “Placement Agent Warrant”). The
Placement Agent Warrant, in the form attached hereto as Exhibit A hereto, shall be exercisable, in whole or in part, commencing
on a date which is six months and one day after the Closing and expiring on the five-year anniversary of the Closing at an exercise
price per share equal to 100% of the purchase price of the Securities. The Placement Agent Warrant and the shares of Common Stock
issuable upon exercise thereof are hereinafter referred to as the “Placement Agent’s Securities.”


 


B. Expense Allowance. Out
of the proceeds of each Closing, the Company also agrees to pay Spartan (a) up to $5,000 reasonable out-of-pocket expenses incurred
for which Spartan shall provide the Company with a detailed invoice and (b) $50,000 for fees and expenses of legal counsel.


 






    	 



    	 



    

 


SECTION 2. REGISTRATION STATEMENT.


 


The Company represents and warrants to, and
agrees with, the Placement Agent that:


 


(A) The Company has filed
with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-3 (Registration
File No. 333-237592) under the Securities Act of 1933, as amended (the “Securities Act”), which became effective
on April 16, 2020, for the registration under the Securities Act of the Securities. At the time of such filing and as of the filing
of the Company’s Form 10-K for the year ended December 31, 2019, the Company met the requirements of Form S-3 under the Securities
Act. Such registration statement meets the requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with
said Rule. The Company will file with the Commission pursuant to Rule 424(b) under the Securities Act, and the rules and regulations
(the “Rules and Regulations”) of the Commission promulgated thereunder, a supplement to the form of prospectus
included in such registration statement relating to the placement of the Shares and the plan of distribution thereof and has advised
the Placement Agent of all further information (financial and other) with respect to the Company required to be set forth therein.
Such registration statement, including the exhibits thereto, as amended at the date of this Agreement, is hereinafter called the
“Registration Statement”; such prospectus in the form in which it appears in the Registration Statement is hereinafter
called the “Base Prospectus”; and the supplemented form of prospectus, in the form in which it will be filed with the
Commission pursuant to Rule 424(b) (including the Base Prospectus as so supplemented) is hereinafter called the “Prospectus
Supplement.” Any reference in this Agreement to the Registration Statement, the Base Prospectus or the Prospectus Supplement
shall be deemed to refer to and include the documents incorporated by reference therein (the “Incorporated Documents”)
pursuant to Item 12 of Form S-3 which were filed under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), on or before the date of this Agreement, or the issue date of the Base Prospectus or the Prospectus Supplement,
as the case may be; and any reference in this Agreement to the terms “amend,” “amendment” or “supplement”
with respect to the Registration Statement, the Base Prospectus or the Prospectus Supplement shall be deemed to refer to and include
the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus or
the Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement
to financial statements and schedules and other information which is “contained,” “included,” “described,”
“referenced,” “set forth” or “stated” in the Registration Statement, the Base Prospectus or
the Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements
and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base
Prospectus or the Prospectus Supplement, as the case may be. No stop order suspending the effectiveness of the Registration Statement
or the use of the Base Prospectus or the Prospectus Supplement has been issued, and no proceeding for any such purpose is pending
or has been initiated or, to the Company’s knowledge, is threatened by the Commission. For purposes of this Agreement, “free
writing prospectus” has the meaning set forth in Rule 405 under the Securities Act and the “Time of Sale Prospectus”
means the Base Prospectus, or the preliminary prospectus, if any, together with the free writing prospectuses, if any, used in
connection with the Shares sold as part of the Placement, including any documents incorporated by reference therein.


 


(B) The Registration Statement
(and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities Act.
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the Securities Act and the Exchange Act and the applicable Rules and Regulations and did not and, as amended or supplemented,
if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Base Prospectus, the Time of Sale Prospectus, if any, and
the Prospectus Supplement, each as of its respective date, comply in all material respects with the Securities Act and the Exchange
Act and the applicable Rules and Regulations. Each of the Base Prospectus, the Time of Sale Prospectus, if any, and the Prospectus
Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material
respects to the requirements of the Exchange Act and the applicable Rules and Regulations, and none of such documents, when they
were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary
to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Base Prospectus or Prospectus
Supplement), in light of the circumstances under which they were made not misleading; and any further documents so filed and incorporated
by reference in the Base Prospectus, the Time of Sale Prospectus, if any, or Prospectus Supplement, when such documents are filed
with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable Rules and
Regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading. No post-effective amendment
to the Registration Statement reflecting any facts or events arising after the date thereof which represent, individually or in
the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission. There are
no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not
been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. There are no contracts
or other documents required to be described in the Base Prospectus, the Time of Sale Prospectus, if any, or Prospectus Supplement,
or to be filed as exhibits or schedules to the Registration Statement, which have not been described or filed as required.


 




    	 



     


    

 


(C) The Company is eligible
to use free writing prospectuses in connection with the Shares sold as part of the Placement pursuant to Rules 164 and 433 under
the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities
Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable
rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to
file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or behalf of or used by the Company complies or
will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations of the
Commission thereunder. The Company will not, without the prior consent of the Placement Agent, prepare, use or refer to, any free
writing prospectus.


 


(D) The Company has delivered,
or will as promptly as practicable deliver, to the Placement Agent complete conformed copies of the Registration Statement and
of each consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies of the Registration Statement
(without exhibits), the Base Prospectus, the Time of Sale Prospectus, if any, and the Prospectus Supplement, as amended or supplemented,
in such quantities and at such places as the Placement Agent reasonably requests. Placement Agent acknowledges that all such materials
as exist on the date of this letter are available on EDGAR. Neither the Company nor any of its directors and officers has distributed
and none of them will distribute, prior to the Closing Date, any offering material in connection with the offering and sale of
the Shares pursuant to the Placement other than the Base Prospectus, the Time of Sale Prospectus, if any, the Prospectus Supplement,
the Registration Statement, copies of the documents incorporated by reference therein and any other materials permitted by the
Securities Act.


 


(E) The Company has the
requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement, the Transaction
Documents with the Purchasers, this Agreement, and the Prospectus Supplement and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of each of this Agreement and the Transaction Documents by the Company and the consummation
by it of the transactions contemplated hereby and thereby and under the Prospectus Supplement have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company, the Company’s Board of Directors
(the “Board of Directors”) or the Company’s stockholders in connection therewith. This Agreement has been
duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies, and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.


 


(F) The execution, delivery
and performance by the Company of this Agreement and the transactions contemplated pursuant to the Transaction Documents and the
Prospectus Supplement, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Company’s or any
Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals (as defined in the Transaction Documents), conflict with or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is
subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to
result in a Material Adverse Effect (as defined in the Securities Purchase Agreement).


 




    	 



     


    

 


SECTION 3. REPRESENTATIONS AND WARRANTIES
INCORPORATED BY REFERENCE. Each of the representations and warranties (together with any related disclosure schedules thereto)
made to the Purchasers in that certain Securities Purchase Agreement dated as of April 24, 2020, between the Company and each Purchaser,
is hereby incorporated herein by reference (as though fully restated herein) and is hereby made to, and in favor of, Spartan.


 


SECTION 4. REPRESENTATIONS OF SPARTAN.
Spartan represents and warrants that it is (i) a member in good standing of FINRA, (ii) registered as a broker/dealer under the
Exchange Act, and (iii) licensed as a broker/dealer under the laws of the States applicable to the offers and sales of Securities
by Spartan. Spartan will immediately notify the Company in writing of any change in its status as such. Spartan covenants that
it will use its “reasonable best efforts” to conduct the Placement hereunder in compliance with the provisions of this
Agreement and the requirements of applicable law. Except as required by law or as contemplated by this Agreement, Spartan will
keep confidential all material nonpublic information, including information regarding the Placement contemplated hereunder, provided
to it by the Company or its affiliates or advisors and use such information only for the purposes contemplated herein.


 


SECTION 5. INDEMNIFICATION. The
Company agrees to the indemnification and other agreements set forth in the Indemnification Provisions (the “Indemnification”)
attached hereto as Addendum A, the provisions of which are incorporated herein by reference and shall survive the termination or
expiration of this Agreement.


 


SECTION 6. ENGAGEMENT TERM. Spartan’s
engagement hereunder will be for 45 days following the date hereof (the “Term”). Following the expiration of the Term,
the engagement may be terminated by either the Company or Spartan at any time upon written notice to the other party. The Company
and Spartan specifically agree that termination of Spartan’s engagement with respect to the Placement will not affect the
parties’ obligations to each other with respect to any other agreements entered into by the parties since January 1, 2020.
Notwithstanding anything to the contrary contained herein, the provisions concerning the Company’s obligation to pay any
fees actually earned and to reimburse expenses actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted
to be reimbursed under FINRA Rule 5110(f)(2)(D), and the confidentiality, indemnification, contribution provisions contained herein
and the Company’s obligations contained in the Indemnification Provisions will survive any expiration or termination of this
Agreement. Spartan agrees not to disclose or use any confidential information concerning the Company provided to it by the Company
for any purposes other than those contemplated under this Agreement or any other agreements entered into by Spartan and the Company
since January 1, 2020.


 


SECTION 7. SPARTAN INFORMATION.
The Company agrees that any information or advice rendered by Spartan in connection with this engagement is for the confidential
use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will not disclose
or otherwise refer to the advice or information in any manner without Spartan’s prior written consent.


 


SECTION 8. NO FIDUCIARY RELATIONSHIP.
This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto,
except those entitled hereto by virtue of the Indemnification Provisions hereof. The Company acknowledges and agrees that Spartan
is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or
the creditors of the Company or any other person by virtue of this Agreement or the retention of Spartan hereunder, all of which
are hereby expressly waived.


 






    	 



    	 



    

 


SECTION 9. CLOSING. The Closing
shall occur at the offices of the Placement Agent (or at such other place as shall be agreed upon by the Placement Agent and the
Company). Subject to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities sold on
such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall
be registered in such name or names and shall be in such denominations, as provided for in the Transaction Documents or otherwise
as the Placement Agent may request at least one business day before the Closing. The obligations of the Placement Agent, and the
closing of the sale of the Securities hereunder are subject to the accuracy, when made and on the Closing Date, of the representations
and warranties on the part of the Company and its Subsidiaries contained herein, to the accuracy of the statements of the Company
and its Subsidiaries made in any certificates pursuant to the provisions hereof, to the performance by the Company and its Subsidiaries
of their obligations hereunder, and to each of the following additional terms and conditions:


 


(A) No stop order suspending
the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall have been initiated
or threatened by the Commission, and any request for additional information on the part of the Commission (to be included in the
Registration Statement, the Base Prospectus or the Prospectus Supplement or otherwise) shall have been complied with to the reasonable
satisfaction of the Placement Agent.


 


(B) The Placement Agent
shall not have discovered and disclosed to the Company on or prior to the Closing Date that the Registration Statement, the Base
Prospectus or the Prospectus Supplement or any amendment or supplement thereto contains an untrue statement of a fact which, in
the opinion of counsel for the Placement Agent, is material or omits to state any fact which, in the opinion of such counsel, is
material and is required to be stated therein or is necessary to make the statements therein not misleading.


 


(C) All corporate proceedings
and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Securities,
the Registration Statement, the Base Prospectus and the Prospectus Supplement and all other legal matters relating to this Agreement
and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Placement
Agent, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable
them to pass upon such matters.


 


(D) The Placement Agent
shall have received from outside counsel to the Company such counsel’s written opinion, addressed to the Placement Agent
and the Purchasers dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agent.


 


(E) (i) Neither the Company
nor any of its Subsidiaries shall have sustained since the date of the latest audited or unaudited financial statements included
or incorporated by reference in the Base Prospectus, any loss or interference with its business from fire, explosion, flood, terrorist
act or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or
decree, otherwise than as set forth in or contemplated by the Base Prospectus of Prospectus Supplement and (ii) since such date
there shall not have been any change in the capital stock or long-term debt of the Company or any of its Subsidiaries or any change,
or any development involving a prospective change, in or affecting the business, general affairs, management, financial position,
stockholders’ equity, results of operations or prospects of the Company and its Subsidiaries, otherwise than as set forth
in or contemplated by the Base Prospectus or Prospectus Supplement, the effect of which, in any such case described in clause (i)
or (ii), is, in the judgment of the Placement Agent, so material and adverse as to make it impracticable or inadvisable to proceed
with the sale or delivery of the Securities on the terms and in the manner contemplated by the Base Prospectus, the Time of Sale
Prospectus, if any, and the Prospectus Supplement.


 


(F) The Common Stock is
registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the effect of terminating
the registration of the Common Stock under the Exchange Act, nor has the Company received any information suggesting that the Commission
is contemplating terminating such registration. The Common Stock shall be registered under the Exchange Act and shall be listed
on the Nasdaq Capital Market, LLC, and the Company shall not have taken any action designed to terminate, or likely to have the
effect of terminating, the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the
Common Stock from Nasdaq Capital Market, LLC, and, other than as publicly disclosed by the Company in filings with the Commission
filed since January 1, 2019, nor shall the Company have received any information suggesting that the Commission or Nasdaq Capital
Market, LLC is contemplating terminating such registration or listing other than as publicly disclosed by the Company in filings
with the Commission.


 


(G) Subsequent to the execution
and delivery of this Agreement, there shall not have occurred any of the following: (i) trading in securities generally on the
New York Stock Exchange or The Nasdaq National Market shall have been suspended or minimum or maximum prices or maximum ranges
for prices shall have been established on any such exchange or such market by the Commission, by such exchange or by any other
regulatory body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been declared by federal or
state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in
the United States, (iii) the United States shall have become engaged in hostilities in which it is not currently engaged, the subject
of an act of terrorism, there shall have been an escalation in hostilities involving the United States, or there shall have been
a declaration of a national emergency or war by the United States, or (iv) there shall have occurred any other calamity or crisis
or any change in general economic, political or financial conditions in the United States or elsewhere, if the effect of any such
event in clause (iii) or (iv) makes it, in the sole judgment of the Placement Agent, impracticable or inadvisable to proceed with
the sale or delivery of the Securities on the terms and in the manner contemplated by the Base Prospectus and the Prospectus Supplement.


 




    	 



     


    

 


(H) No action shall have
been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body
which would, as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely affect or potentially
and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature
by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance
or sale of the Securities or materially and adversely affect or potentially and adversely affect the business or operations of
the Company.


 


(I) The Company shall have
prepared and filed with the Commission a Current Report on Form 8-K with respect to the Placement, including as an exhibit thereto
this Agreement.


 


(J) The Company shall have
entered into subscription agreements with each of the Purchasers and such agreements shall be in full force and effect and shall
contain representations, warranties and covenants of the Company as agreed between the Company and the Purchasers.


 


(K) FINRA shall have raised
no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall,
if requested by the Placement Agent, make or authorize Placement Agent’s counsel to make on the Company’s behalf, an
Issuer Filing with FINRA pursuant to FINRA Rule 5110 with respect to the Registration Statement and pay all filing fees required
in connection therewith.


 


(L) Prior to the Closing
Date, the Company shall have furnished to the Placement Agent such further information, certificates and documents as the Placement
Agent may reasonably request, including a certificate of the Chief Financial Officer with respect to certain financial information
set forth in the Company’s public reports.


 


(M) Prior to the Closing
Date, the Company shall have furnished to the Placement Agent a certificate, dated the Closing Date, of its Chief Executive Officer
and its Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement, the Base Prospectus
and the Prospectus Supplement and, in their opinion, Registration Statement, as of its effective date, did not include any untrue
statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Registration Statement, the Base Prospectus or the Prospectus Supplement, as of the time of execution
of this Agreement through the Closing Date, did not include any untrue statement of a material fact and did not omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not
misleading, (ii) since the filing of the most recent Form 10-K, no event has occurred which should have been set forth in a supplement
or amendment to the Registration Statement, the Base Prospectus or the Prospectus Supplement, and (iii) to their knowledge after
reasonable investigation, as of the Closing Date, the representations and warranties of the Company in this Agreement are true
and correct, and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied
hereunder at or prior to the Closing Date.


 


(N) As of the Closing Date,
the Placement Agent shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing
Date, certifying: (i) that each of the Company’s certificate of incorporation and bylaws is true and complete, has not been
modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors relating to the Placement
are in full force and effect and have not been modified; and (iii) the good standing of the Company and its subsidiaries. The documents
referred to in such certificate shall be attached to such certificate.


 


All opinions, letters,
evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions
hereof only if they are in form and substance reasonably satisfactory to counsel for the Placement Agent.


 




    	 



     


    

 


SECTION 10. GOVERNING LAW. This
Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made
and to be performed entirely in such State. This Agreement may not be assigned by either party without the prior written consent
of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors
and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or
conduct in connection herewith is waived. Each of the Placement Agent and the Company: (i) agrees that any legal suit, action or
proceeding arising out of or relating to this Agreement and/or the transactions contemplated hereby shall be instituted exclusively
in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii)
waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably
consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern
District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company further agrees to accept
and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme
Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service
of process upon the Company mailed by certified mail to the Company’s address shall be deemed in every respect effective
service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Placement Agent mailed
by certified mail to the Placement Agent’s address shall be deemed in every respect effective service process upon the Placement
Agent, in any such suit, action or proceeding. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of a Transaction
Document, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.


 


SECTION 11. ENTIRE AGREEMENT/MISC.
This Agreement (including the attached Indemnification Provisions) embodies the entire agreement and understanding between the
parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof. If any provision
of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision
in any other respect or any other provision of this Agreement, which will remain in full force and effect. This Agreement may not
be amended or otherwise modified or waived except by an instrument in writing signed by both Spartan and the Company. The representations,
warranties, agreements and covenants contained herein shall survive the closing of the Placement and delivery and/or exercise of
the Securities, as applicable. This Agreement may be executed in two or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or a .pdf format file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature
page were an original thereof. The Company agrees that the Placement Agent may rely upon, and is a third party beneficiary of,
the representations and warranties, and applicable covenants set forth in any such purchase, subscription or other agreement with
the Purchasers in the Placement.


 


SECTION 12. CONFIDENTIALITY.
The Placement Agent (i) will keep the Confidential Information (as such term is defined below) confidential and will not (except
as required by applicable law or stock exchange requirement, regulation or legal process), without the Company’s prior written
consent, disclose to any person any Confidential Information, and (ii) will not use any Confidential Information other than in
connection with its evaluation of the Transaction. The Placement Agent further agrees to disclose the Confidential Information
only to its Representatives who need to know the Confidential Information for the purpose of evaluating the Transaction, and who
are informed by the Placement Agent of the confidential nature of the Confidential Information. The term “Confidential
Information” shall mean, all confidential, proprietary and non-public information (whether written, oral or electronic
communications) furnished by the Company to the Placement Agent or its Representatives in connection with the Placement Agent’s
evaluation of the Transaction, which information is (a) clearly marked as “confidential” or with a similar designation,
or (b) if disclosed orally or otherwise than in writing, is identified as confidential and/or proprietary at the time of disclosure
by the Company. Information communicated orally or otherwise than in writing, shall only be considered Confidential Information
if such information is designated as being confidential at the time of disclosure (or promptly thereafter) and is reduced in writing
and identified to the Placement Agent as being Confidential Information immediately after the initial disclosure. The term “Confidential
Information” will not, however, include information which (i) is or becomes publicly available other than as a result
of a disclosure by the Placement Agent or its Representatives in violation of this Agreement, or (ii) is known to the Placement
Agent or any of its Representatives prior to disclosure by the Company or any of its Representatives. The term “Representatives”
shall mean a party’s directors, board committees, officers, employees, financial advisors, attorneys and accountants. This
provision shall be in full force and effect for two years.


 


SECTION 13. NOTICES. Any and
all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a
business day, (b) the next business day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New
York City time) on any business day, (c) the business day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as set forth on the signature pages hereto.


 


[The remainder of this page has been intentionally
left blank.]


 




    	 



     


    

 


Please confirm that the
foregoing correctly sets forth our agreement by signing and returning to Spartan the enclosed copy of this Agreement.


 


	 	Very truly yours,
	 	 
	 	SPARTAN CAPITAL SECURITIES, LLC
	 	 
	 	By:	                                        
	 	Name:	Jason Diamond
	 	Title:	Head of Investment Banking
	 	 
	 	Addresses for notice:
	 	Spartan Capital Securities, LLC
	 	789 N. Water Street, Suite 400
	 	Milwaukee, WI 53202
	 	
        Attention: Jason Diamond

        Email: jdiamond@spartancapital.com



 





	 	Spartan
    Capital Securities, LLC
	 	45
    Broadway
	 	New
    York, NY 10006
	 	Attn:
    Kim Monchik
	 	kmonchik@spartancapital.com
	 	 
	 	with
    a copy that shall not constitute notice to:
	 	Lucosky
    Brookman LLP
	 	101
    Wood Avenue South
	 	Iselin,
    NJ 08830







 


Accepted and Agreed to as of


the date first written above:


 


	Hancock Jaffe Laboratories, Inc.	 
	 	 
	By:	 	 
	Name:	Robert A Berman	 
	Title:	Chief Executive Officer	 


 


Address for notice:


Hancock Jaffe Laboratories, Inc.


70 Doppler


Irvine, CA 92618


Attn: Robert A Berman, Chief Executive Officer


 




    	 



     


    

 


ADDENDUM A


 


INDEMNIFICATION PROVISIONS


 


In connection with the
engagement of Spartan Capital Securities, LLC (“Spartan”) by Hancock Jaffe Laboratories, Inc. (the “Company”)
pursuant to a letter agreement dated April 24, 2020, between the Company and Spartan, as it may be amended from time to time in
writing (the “Agreement”), the Company hereby agrees as follows:


 


	1.	The Company hereby agrees to indemnify and hold Spartan, its officers, directors, principals, employees, affiliates, and stockholders, and their successors and assigns, harmless from and against any and all loss, claim, damage, liability, deficiencies, actions, suits, proceedings, costs and legal expenses or expense whatsoever (including, but not limited to, reasonable legal fees and other expenses and reasonable disbursements incurred in connection with investigating, preparing to defend or defending any action, suit or proceeding, including any inquiry or investigation, commenced or threatened, or any claim whatsoever, or in appearing or preparing for appearance as witness in any proceeding, including any pretrial proceeding such as a deposition) (collectively the “Losses”) arising out of, based upon, or in any way related or attributed to, (i) any breach of a representation, warranty or covenant by the Company contained in this Agreement; (ii) the Registration Statement, the Base Prospectus, or the Prospectus Supplement (as from time to time each may be amended and supplemented); (iii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Placement, including any “road show” or investor presentations made to investors by the Company (whether in person or electronically); or (iv) any activities or services performed hereunder by Spartan, unless it is finally judicially determined in a court of competent jurisdiction that such Losses were the primary and direct result of the intentional misconduct or gross negligence of Spartan in performing the services hereunder or information provided by Spartan expressly for inclusion in the Prospectus Supplement.
	 	 
	2.	If Spartan receives written notice of the commencement of any legal action, suit or proceeding with respect to which the Company is or may be obligated to provide indemnification pursuant to this Section (B), Spartan shall, within twenty (20) days of the receipt of such written notice, give the Company written notice thereof (a “Claim Notice”). Failure to give such Claim Notice within such twenty (20) day period shall not constitute a waiver by Spartan of its right to indemnity hereunder with respect to such action, suit or proceeding; provided, however, the indemnification hereunder may be limited by any such failure to provide a Claim Notice to the Company that materially prejudices the Company. Upon receipt by the Company of a Claim Notice from Spartan with respect to any claim for indemnification which is based upon a claim made by a third party (“Third Party Claim”), the Company may assume the defense of the Third Party Claim with counsel reasonably satisfactory to Spartan, as described below. Spartan shall cooperate in the defense of the Third Party Claim and shall furnish such records, information and testimony and attend all such conferences, discovery proceedings, hearings, trial and appeals as may be reasonably required in connection therewith. Spartan shall have the right to employ its own counsel in any such action which shall be at the Company’s expense if (i) the Company and Spartan shall have mutually agreed in writing to the retention of such counsel, (ii) the Company shall have failed in a timely manner to assume the defense and employ counsel or experts reasonably satisfactory to Spartan in such litigation or proceeding or (iii) the named parties to any such litigation or proceeding (including any impleaded parties) include the Company and Spartan and representation of the Company and Spartan by the same counsel or experts would, in the reasonable opinion of Spartan, be inappropriate due to actual or potential differing interests between the Company and Spartan. The Company shall not satisfy or settle any Third Party Claim for which indemnification has been sought and is available hereunder, without the prior written consent of Spartan, which consent shall not be delayed and which shall not be required if Spartan is granted an unconditional release in connection therewith in such form as reasonably acceptable to Spartan, and if such release does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of Spartan, or its officers, directors, principals, employees, affiliates, and stockholders. The indemnification provisions hereunder shall survive the termination or expiration of this Agreement.


 




    	 



     


    

 


	3.	The Company further agrees, upon demand by Spartan, to promptly advance and/or reimburse Spartan for, or pay, any loss, claim, damage, liability or expense as to which Spartan has been indemnified herein with such reimbursement to be made currently as any loss, damage, liability or expense is incurred by Spartan. Notwithstanding the provisions of the aforementioned Indemnification, any such advancement, reimbursement or payment by the Company of fees, expenses, or disbursements incurred by Spartan shall be repaid by Spartan in the event of any proceeding in which a final judgment (after all appeals or the expiration of time to appeal) is entered in a court of competent jurisdiction against Spartan based solely upon its gross negligence or intentional misconduct in the performance of its duties hereunder or the information provided by Spartan expressly for inclusion in the Prospectus Supplement, and provided further, that the Company shall not be required to make reimbursement or payment for any settlement effected without the Company’s prior written consent (which consent shall not be unreasonably withheld or delayed).
	 	 
	4.	If for any reason the foregoing indemnification is unavailable or is insufficient to hold such indemnified party harmless, the Company agrees to contribute the amount paid or payable by such indemnified party in such proportion as to reflect not only the relative benefits received by the Company, as the case may be, on the one hand, and Spartan, on the other hand, but also the relative fault of the Company and Spartan as well as any relevant equitable considerations. In no event shall Spartan contribute in excess of the fees actually received by it pursuant to the terms of this Agreement.
	 	 
	5.	For purposes of this Agreement, each officer, director, stockholder, and employee or affiliate of Spartan and each person, if any, who controls Spartan (or any affiliate) within the meaning of either Section 15 of the Securities Act of 1933, as amended, or Section 20 of the Securities Exchange Act of 1934, as amended, shall have the same rights as Spartan with respect to matters of indemnification by the Company hereunder.


 


	 	SPARTAN CAPITAL SECURITIES, LLC
	 	 
	 	 	 
	 	Name:	Jason Diamond
	 	Title:	Head of Investment Banking


 


Accepted and Agreed to as of


the date first written above:


 


	Hancock Jaffe Laboratories, Inc.	 
	 	 
	By:	 	 
	Name:	Robert A Berman	 
	Title:	Chief Executive Officer